Curanex Pharmaceuticals Announces Pricing Of $15M Initial Public Offering Of 3.75M Shares At A Price Of $4/Share

Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the "Offering") of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The Company's shares of common stock are expected to begin trading on the Nasdaq Capital Market on August 26, 2025, under the ticker symbol "CURX."

The Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering, to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses. The Offering is expected to close on August 27, 2025, subject to customary closing conditions.

The Company intends to use the proceeds from the Offering for: (i) the development of our lead product candidate, Phyto-N, for the treatment of ulcerative colitis; (ii) to conduct FDA-required good laboratory practice ("GLP") toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, (iii) to prepare and submit an Investigational New Drug (IND) application, and (iv) for working capital and other general corporate purposes.